Literature DB >> 21353629

Immunoglobulin G and M antibodies to human parvovirus 4 (PARV4) are frequently detected in patients with HIV-1 infection.

Shiu-Ju Yang1, Chien-Ching Hung, Sui-Yuan Chang, Kuang-Lun Lee, Mao-Yuan Chen.   

Abstract

BACKGROUND: The transmission routes of PARV4 are not completely understood. The first PARV4 serological study suggested that PARV4 is transmitted predominantly through parenteral route.
OBJECTIVES: To set up an immunoblot system for studying the epidemiology of PARV4 infection in HIV-1 infected patients in Taiwan. STUDY
DESIGN: Recombinant fusion proteins SUMOVP2 (a.a. 272-630 of PARV4 open reading frame 2) and SUMOVP3 (a.a. 604-914) were made and used as antigens in immunoblot. Plasma samples were from HIV-1 infected intravenous drug users IDU (69), homosexuals (66) and heterosexuals (68).
RESULTS: PARV4 IgG seropositive rate was 73.9%, 71.2% and 58.8%; IgM seropositive rate was 40.5%, 16.7% and 17.6% in IDUs, homosexuals and heterosexuals, respectively. Longitudinal samples were available from two homosexuals positive for IgM anti-PARV4, persistent IgM response was found over a period of 9 and 21 months, respectively.
CONCLUSIONS: PARV4 is a common viral infection in HIV-1 infected homosexuals and heterosexuals in Taiwan. The detection of IgM anti-PARV4 does not always suggest recent PARV4 infection.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21353629     DOI: 10.1016/j.jcv.2011.01.017

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  9 in total

1.  Human parvovirus 4 in the blood supply and transmission by pooled plasma-derived clotting factors: does it matter?

Authors:  Eric Delwart
Journal:  Transfusion       Date:  2012-07       Impact factor: 3.157

2.  Acute diarrhea in West African children: diverse enteric viruses and a novel parvovirus genus.

Authors:  Tung G Phan; Nguyen P Vo; Isidore J O Bonkoungou; Amit Kapoor; Nicolas Barro; Miguel O'Ryan; Beatrix Kapusinszky; Chunling Wang; Eric Delwart
Journal:  J Virol       Date:  2012-08-01       Impact factor: 5.103

3.  Human parvovirus 4 in nasal and fecal specimens from children, Ghana.

Authors:  Jan Felix Drexler; Ulrike Reber; Doreen Muth; Petra Herzog; Augustina Annan; Fabian Ebach; Nimarko Sarpong; Samuel Acquah; Julia Adlkofer; Yaw Adu-Sarkodie; Marcus Panning; Egbert Tannich; Jürgen May; Christian Drosten; Anna Maria Eis-Hübinger
Journal:  Emerg Infect Dis       Date:  2012-10       Impact factor: 6.883

4.  No evidence of presence of parvovirus 4 in a Swedish cohort of severely immunocompromised children and adults.

Authors:  Thomas Tolfvenstam; Oscar Norbeck; Lars Ohrmalm
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

5.  Discovery and genomic characterization of a novel ovine partetravirus and a new genotype of bovine partetravirus.

Authors:  Herman Tse; Hoi-Wah Tsoi; Jade L L Teng; Xin-Chun Chen; Haiying Liu; Boping Zhou; Bo-Jian Zheng; Patrick C Y Woo; Susanna K P Lau; Kwok-Yung Yuen
Journal:  PLoS One       Date:  2011-09-27       Impact factor: 3.240

6.  Placental transmission of human parvovirus 4 in newborns with hydrops, Taiwan.

Authors:  Mao-Yuan Chen; Shiu-Ju Yang; Chien-Ching Hung
Journal:  Emerg Infect Dis       Date:  2011-10       Impact factor: 6.883

7.  Detection of human parvovirus 4 viremia in the follow-up blood samples from seropositive individuals suggests the existence of persistent viral replication or reactivation of latent viral infection.

Authors:  Mao-Yuan Chen; Chien-Ching Hung; Kuang-Lun Lee
Journal:  Virol J       Date:  2015-06-19       Impact factor: 4.099

Review 8.  Human parvovirus 4 'PARV4' remains elusive despite a decade of study.

Authors:  Philippa C Matthews; Colin Sharp; Peter Simmonds; Paul Klenerman
Journal:  F1000Res       Date:  2017-01-27

9.  Evolution of CD8+ T cell responses after acute PARV4 infection.

Authors:  Ruth Simmons; Colin Sharp; Jordana Levine; Paul Bowness; Peter Simmonds; Andrea Cox; Paul Klenerman
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.